In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.
Tim Smith
Advertisement
Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing.
Articles by Tim Smith
Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.
The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.
The federal agency gave the nod to Verrica Pharmaceuticals for its therapy, VP-102 (Ycanthe), for molluscum contagiosum (molluscum), making it the first treatment indicated for the viral-borne skin disease.
Advertisement
Latest Updated Articles
Investigational Hepatitis D Therapy Well-Tolerated, Safe for Chronic Disease at Week 48Published: December 15th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
2
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
3
High Continued Adherence of Lenacapavir in Individuals Who Use Substances and Alcohol
4
Risk Stratification, Testing, and Treatment in Recurrent Clostridioides difficile
5
